AKTS Latest Press Releases

-- October 1, 2026 --

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 Globe Newswire 8:00 AM

-- September 9, 2026 --

Aktis Oncology to Present at Upcoming September Investor Conferences Globe Newswire 8:00 AM

-- August 13, 2026 --

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 Globe Newswire 4:01 PM

-- May 27, 2026 --

Aktis Oncology to Present at the Jefferies Global Healthcare Conference Globe Newswire 4:05 PM

-- May 21, 2026 --

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors Globe Newswire 5:21 PM

-- May 11, 2026 --

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software